|
US5081227A
(en)
|
1988-03-04 |
1992-01-14 |
La Jolla Cancer Research Foundation |
Germ cell alkaline phosphatase
|
|
KR970007782B1
(ko)
|
1989-11-17 |
1997-05-16 |
유니레버 엔 브이 |
특이적 결합제
|
|
US6773669B1
(en)
|
1995-03-10 |
2004-08-10 |
Maxcyte, Inc. |
Flow electroporation chamber and method
|
|
US6090617A
(en)
|
1996-12-05 |
2000-07-18 |
Entremed, Inc. |
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
|
|
US20020004490A1
(en)
|
1999-04-12 |
2002-01-10 |
Dean Nicholas M. |
Antisense modulation of Fas mediated signaling
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
GB9827152D0
(en)
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
AU776150B2
(en)
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
MXPA01011950A
(es)
|
1999-05-27 |
2002-05-06 |
Gov Health & Human Serv |
Inmunoconjugados que tienen alta afinidad de enlace.
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
JP2003531616A
(ja)
|
2000-04-28 |
2003-10-28 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
細胞性クロマチンに外因性分子を結合させるための方法
|
|
US7029916B2
(en)
|
2001-02-21 |
2006-04-18 |
Maxcyte, Inc. |
Apparatus and method for flow electroporation of biological samples
|
|
JP4070611B2
(ja)
|
2001-04-23 |
2008-04-02 |
アマクサ アーゲー |
電気穿孔法用の緩衝溶液およびその使用を含む方法
|
|
KR100385905B1
(ko)
|
2001-05-17 |
2003-06-02 |
주식회사 웰진 |
유니진 유래의 안티센스 분자로 구성된 안티센스 라이브러리를 이용한 대규모 유전자 검색 및 기능 분석 방법
|
|
US6485974B1
(en)
|
2001-05-18 |
2002-11-26 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTPN2 expression
|
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
|
DK2574662T3
(da)
|
2001-08-22 |
2021-09-20 |
Maxcyte Inc |
Fremgangsmåde til elektroporation af biologiske prøver
|
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
|
AU2002343792A1
(en)
|
2001-11-28 |
2003-06-10 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
|
EP1504092B2
(en)
|
2002-03-21 |
2014-06-25 |
Sangamo BioSciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US20040121353A1
(en)
|
2002-05-23 |
2004-06-24 |
Ceptyr, Inc. |
Modulation of TCPTP signal transduction by RNA interference
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
WO2004030634A2
(en)
|
2002-10-02 |
2004-04-15 |
Alnylam Pharmaceuticals Inc. |
Therapeutic compositions
|
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
|
CN1836048A
(zh)
|
2003-06-10 |
2006-09-20 |
图尔金株式会社 |
可转导的dna结合蛋白
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
DE502004009820D1
(de)
|
2004-03-15 |
2009-09-10 |
Lonza Cologne Ag |
Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
|
|
WO2005113820A2
(en)
|
2004-05-12 |
2005-12-01 |
Maxcyte, Inc. |
Methods and devices related to a regulated flow electroporation chamber
|
|
RU2006143560A
(ru)
|
2004-06-12 |
2008-07-20 |
Диджитал Био Технолоджи Ко |
Устройство для электропорации с удлиненным полым элементом
|
|
WO2005123962A2
(en)
|
2004-06-14 |
2005-12-29 |
The University Of Texas At Austin |
Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
|
|
ES2465467T3
(es)
|
2004-06-14 |
2014-06-05 |
Lonza Cologne Ag |
Procedimiento y disposición de circuito para el tratamiento de material biológico
|
|
JP2008521437A
(ja)
|
2004-11-30 |
2008-06-26 |
マックスサイト インコーポレーティッド |
コンピュータ化されたエレクトロポレーション
|
|
EP1824872B1
(en)
|
2004-12-14 |
2012-02-08 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of mll-af4 and uses thereof
|
|
WO2006124641A2
(en)
|
2005-05-12 |
2006-11-23 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Anti-mesothelin antibodies useful for immunological assays
|
|
DK1907000T4
(da)
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
|
EP2325332B1
(en)
|
2005-08-26 |
2012-10-31 |
DuPont Nutrition Biosciences ApS |
Use of CRISPR associated genes (CAS)
|
|
US20070161031A1
(en)
|
2005-12-16 |
2007-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional arrays for high throughput characterization of gene expression regulatory elements
|
|
JP2010500029A
(ja)
|
2006-08-11 |
2010-01-07 |
ダウ アグロサイエンシィズ エルエルシー |
ジンクフィンガーヌクレアーゼ媒介相同組換え
|
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
WO2008109532A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fas gene expression and uses thereof
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
JP5779090B2
(ja)
|
2008-04-09 |
2015-09-16 |
マックスサイト インコーポレーティッド |
新規に単離された細胞の治療組成物の操作および送達
|
|
EP2310500B1
(en)
|
2008-07-18 |
2015-03-11 |
Maxcyte, Inc. |
Methods for optimizing electroporation
|
|
ES2563984T3
(es)
*
|
2008-10-22 |
2016-03-17 |
Quark Pharmaceuticals, Inc. |
Métodos para el tratamiento de trastornos oculares
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
WO2010129023A2
(en)
|
2009-04-28 |
2010-11-11 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
EP2539445B1
(en)
|
2010-02-26 |
2018-03-21 |
Cellectis |
Use of endonucleases for inserting transgenes into safe harbor loci
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
BR112014020502A2
(pt)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
|
|
KR20210149195A
(ko)
|
2012-07-13 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 t 세포의 투여 적합성을 평가하는 방법
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
WO2014082163A1
(en)
|
2012-11-28 |
2014-06-05 |
Zhou Youwen |
Tox inhibition for the treatment of cancer
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
KR102955556B1
(ko)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201507026WA
(en)
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
WO2014124267A1
(en)
|
2013-02-07 |
2014-08-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
|
|
IL305629A
(en)
|
2013-02-15 |
2023-11-01 |
Univ California |
Chimeric antigen receptor and methods of using it
|
|
JP6257655B2
(ja)
|
2013-03-01 |
2018-01-10 |
アメリカ合衆国 |
末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
|
|
HK1220614A1
(zh)
|
2013-03-10 |
2017-05-12 |
Baylor College Of Medicine |
耐化疗免疫细胞
|
|
US20160145348A1
(en)
|
2013-03-14 |
2016-05-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
CN105408483A
(zh)
|
2013-03-15 |
2016-03-16 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CN105121650A
(zh)
|
2013-04-02 |
2015-12-02 |
拜尔作物科学公司 |
真核生物中的靶向基因组工程
|
|
EP3789487A1
(en)
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
|
|
CA2912389C
(en)
|
2013-06-10 |
2020-01-28 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Methods and compositions for reducing immunosupression by tumor cells
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
EP3058072B1
(en)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US9951353B2
(en)
|
2013-11-15 |
2018-04-24 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
KR20160097338A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
|
JP2016539653A
(ja)
|
2013-12-13 |
2016-12-22 |
セレクティス |
微小藻類のゲノム操作のためのCas9ヌクレアーゼプラットフォーム
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
KR102415811B1
(ko)
|
2014-01-31 |
2022-07-04 |
팩터 바이오사이언스 인크. |
핵산 제조 및 송달을 위한 방법 및 산물
|
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
|
JP6665102B2
(ja)
|
2014-02-21 |
2020-03-13 |
セレクティスCellectis |
制御性t細胞をインサイチューで阻害するための方法
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
SG10201808811QA
(en)
|
2014-04-10 |
2018-11-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Method and compositions for cellular immunotherapy
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
JP2017524348A
(ja)
|
2014-06-10 |
2017-08-31 |
モナッシュ ユニバーシティ |
養子細胞移入のためのptpn2阻害を用いた白血球の産生方法
|
|
CN104131095A
(zh)
*
|
2014-07-25 |
2014-11-05 |
封志纯 |
用于原发性免疫缺陷病基因筛查的引物组合物和试剂盒
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
CN113930455A
(zh)
|
2014-10-09 |
2022-01-14 |
生命技术公司 |
Crispr寡核苷酸和基因剪辑
|
|
KR102546296B1
(ko)
|
2014-10-31 |
2023-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
|
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
|
EP3247328B1
(en)
|
2015-01-21 |
2026-01-07 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
EP3247368A4
(en)
|
2015-01-23 |
2019-01-02 |
Musc Foundation for Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
|
US20190388469A1
(en)
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US12129471B2
(en)
|
2015-02-23 |
2024-10-29 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
EP3262166A4
(en)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
WO2016172359A2
(en)
|
2015-04-24 |
2016-10-27 |
The Regents Of The University Of California |
Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
EP3310932B1
(en)
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
|
US11555207B2
(en)
|
2015-06-17 |
2023-01-17 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
|
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CN107207613B
(zh)
|
2015-08-07 |
2020-06-09 |
深圳市体内生物医药科技有限公司 |
含Toll样受体胞内结构域的嵌合抗原受体
|
|
TWI811023B
(zh)
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017035659A1
(en)
|
2015-09-01 |
2017-03-09 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
|
|
CA2999070A1
(en)
*
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
WO2017070169A1
(en)
|
2015-10-19 |
2017-04-27 |
The Methodist Hospital |
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
|
|
US20180312873A1
(en)
|
2015-10-20 |
2018-11-01 |
10X Genomics, Inc. |
Method and systems for high throughput single cell genetic manipulation
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
US12642852B1
(en)
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
AU2016359629B2
(en)
|
2015-11-23 |
2023-03-09 |
Ranjan BATRA |
Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
|
|
EP3383920B1
(en)
|
2015-11-30 |
2024-01-10 |
The Regents of the University of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
EP3397760A2
(en)
|
2015-12-30 |
2018-11-07 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
US20190241910A1
(en)
|
2016-03-11 |
2019-08-08 |
Bluebird Bio, Inc. |
Genome edited immune effector cells
|
|
US20170267755A1
(en)
|
2016-03-16 |
2017-09-21 |
Sri International |
Isolated anti-mesothelin antibodies, conjugates and uses thereof
|
|
AU2017248259A1
(en)
|
2016-04-07 |
2018-10-25 |
Bluebird Bio, Inc. |
Chimeric antigen receptor T cell compositions
|
|
EP4166161B1
(en)
|
2016-04-14 |
2026-03-04 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
KR102614675B1
(ko)
|
2016-04-15 |
2023-12-19 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
|
WO2017189336A1
(en)
|
2016-04-25 |
2017-11-02 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
|
EP3448995A1
(en)
|
2016-04-25 |
2019-03-06 |
Universität Basel |
Allele editing and applications thereof
|
|
KR102370675B1
(ko)
|
2016-04-29 |
2022-03-04 |
바스프 플랜트 사이언스 컴퍼니 게엠베하 |
표적 핵산의 변형을 위한 개선된 방법
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2017210334A1
(en)
|
2016-05-31 |
2017-12-07 |
Massachusetts Institute Of Technology |
Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
|
|
US11713458B2
(en)
|
2016-06-20 |
2023-08-01 |
Octapharma Ag |
Means and methods for modifying multiple alleles
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
CA3029121A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
US11466291B2
(en)
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2018039084A1
(en)
|
2016-08-20 |
2018-03-01 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeablization of cells
|
|
CA3034093A1
(en)
|
2016-08-23 |
2018-03-01 |
The Regents Of The University Of California |
Proteolytically cleavable chimeric polypeptides and methods of use thereof
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018058064A1
(en)
|
2016-09-23 |
2018-03-29 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
AU2017341736B2
(en)
|
2016-10-12 |
2022-09-08 |
Feldan Bio Inc. |
Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
AU2017362513A1
(en)
|
2016-11-18 |
2019-05-16 |
Christopher Bradley |
Massively multiplexed homologous template repair for whole-genome replacement
|
|
RU2019121801A
(ru)
|
2016-12-14 |
2021-01-15 |
Лигандал, Инк. |
Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
|
|
CN110603265B
(zh)
|
2017-01-09 |
2024-01-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
US12275963B2
(en)
|
2017-05-08 |
2025-04-15 |
Toolgen Incorporated |
Artificially manipulated immune cell
|
|
WO2018222880A1
(en)
|
2017-05-31 |
2018-12-06 |
Trustees Of Boston University |
Mechano-activated control of gene expression
|
|
MY200418A
(en)
|
2017-06-15 |
2023-12-25 |
Univ California |
Targeted non-viral dna insertions
|
|
WO2019079034A1
(en)
|
2017-10-17 |
2019-04-25 |
The General Hospital Corporation |
METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES
|
|
SG11202003798TA
(en)
|
2017-10-27 |
2020-05-28 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
|
US12698499B2
(en)
|
2017-10-27 |
2026-08-04 |
The Trustees Of The University Of Pennsylvania |
Identifying epigenetic and transcriptional targets to prevent and reverse T cell exhaustion
|
|
CN111601882A
(zh)
|
2017-11-22 |
2020-08-28 |
拉霍拉敏感及免疫学研究所 |
工程化的免疫细胞的应用和生产
|
|
KR102327512B1
(ko)
|
2018-01-12 |
2021-11-17 |
주식회사 큐로셀 |
이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
|
|
WO2019160956A1
(en)
*
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3755712A1
(en)
*
|
2018-02-21 |
2020-12-30 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
|
CA3092459A1
(en)
|
2018-03-02 |
2019-09-06 |
Generation Bio Co. |
Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
|
|
WO2019178422A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
US20210207174A1
(en)
|
2018-05-25 |
2021-07-08 |
The Regents Of The University Of California |
Genetic engineering of endogenous proteins
|
|
EP3806894A4
(en)
|
2018-06-12 |
2022-06-08 |
Promab Biotechnologies, Inc. |
PLAP-CAR EFFECTOR CELLS
|
|
US12473533B2
(en)
|
2018-07-09 |
2025-11-18 |
The Regents Of The University Of California |
Gene targets for T-cell-based immunotherapy
|
|
US20220081691A1
(en)
|
2018-08-07 |
2022-03-17 |
Dana-Farber Cancer Institute, Inc |
Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
|
|
KR102879284B1
(ko)
|
2018-08-29 |
2025-10-31 |
난징 레전드 바이오테크 씨오., 엘티디. |
항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
|
|
CN110904045A
(zh)
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
WO2020072125A1
(en)
|
2018-10-03 |
2020-04-09 |
Massachusetts Institute Of Technology |
Splicing-dependent transcriptional gene silencing or activation
|
|
AU2019386140B2
(en)
|
2018-11-28 |
2026-05-28 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020123871A1
(en)
|
2018-12-12 |
2020-06-18 |
The Regents Of The University Of California |
Compositions and methods for modifying a target nucleic acid
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
|
KR20210116526A
(ko)
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
SG11202108452WA
(en)
|
2019-02-04 |
2021-09-29 |
Ksq Therapeutics Inc |
Combination gene targets for improved immunotherapy
|
|
WO2020186219A1
(en)
|
2019-03-14 |
2020-09-17 |
The Regents Of The University Of California |
Pooled knock-in screening and heterologous polypeptides co-expressed under the control of endogenous loci
|
|
US20220226380A1
(en)
|
2019-04-24 |
2022-07-21 |
St. Jude Children's Research Hospital, Inc. |
Gene knock-outs to improve t cell function
|
|
CN114127268A
(zh)
|
2019-05-02 |
2022-03-01 |
塞利亚德股份公司 |
具有多重化的抑制性rna的细胞
|
|
US11162102B2
(en)
*
|
2019-05-13 |
2021-11-02 |
Dna Twopointo Inc. |
Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
|
|
CN110343667A
(zh)
*
|
2019-07-17 |
2019-10-18 |
贝赛尔特(北京)生物技术有限公司 |
工程化的免疫细胞及其制备方法和应用
|
|
CA3150095A1
(en)
*
|
2019-09-06 |
2021-03-11 |
Shirley O'dea |
Engineering of immune cells for ex vivo cell therapy applications
|
|
DE102019214466A1
(de)
|
2019-09-23 |
2021-03-25 |
Henkel Ag & Co. Kgaa |
Mittel zum Färben von keratinischem Material mit Aminosilikon, farbgebender Verbindung und ethoxyliertem Fettsäureester
|
|
US20220372101A1
(en)
|
2019-09-24 |
2022-11-24 |
The Regents Of The University Of California |
Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
|
|
WO2021061859A1
(en)
|
2019-09-24 |
2021-04-01 |
The Regents Of The University Of California |
Novel receptors for ligand-dependent transcriptional regulation
|
|
WO2021061862A1
(en)
|
2019-09-24 |
2021-04-01 |
The Regents Of The University Of California |
Notch receptors with hinge domain
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
EP4061927A4
(en)
|
2019-11-20 |
2024-11-13 |
Cartherics Pty. Ltd. |
METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
|
|
CA3163258A1
(en)
|
2019-11-27 |
2021-06-03 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of nk cells
|
|
EP4065138A4
(en)
|
2019-11-27 |
2024-02-28 |
Board of Regents, The University of Texas System |
LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS
|
|
WO2021108650A1
(en)
|
2019-11-27 |
2021-06-03 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of b cells
|
|
EP4097139A4
(en)
|
2020-01-28 |
2024-03-27 |
Promab Biotechnologies, Inc. |
PLAP-CD3 EPSILON BISPECIFIC ANTIBODIES
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
WO2021207526A1
(en)
|
2020-04-09 |
2021-10-14 |
The Regents Of The University Of California |
Humanized notch receptors with hinge domain
|
|
WO2022093846A1
(en)
|
2020-10-26 |
2022-05-05 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
WO2022150831A1
(en)
|
2021-01-07 |
2022-07-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Car cells and polyspecific binding molecules for treating solid tumor
|
|
US20220235380A1
(en)
*
|
2021-01-26 |
2022-07-28 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US12592129B2
(en)
|
2021-10-05 |
2026-03-31 |
Aristocrat Technologies, Inc. |
Electronic gaming machine with symbols streaming adjacent an active reel matrix with reel expansion and symbol absorption processes
|
|
WO2023064876A1
(en)
|
2021-10-14 |
2023-04-20 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|